The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The guidelines are part of a national trend by municipal governments and private firms struggling to manage ballooning costs ...
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
But the FDA has approved weight loss drugs that contain the same active ingredients as Ozempic and Mounjaro. Wegovy (semaglutide) and Zepbound (tirzepatide) are prescription injections that are ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...